Waldenström's macroglobulinemia screening: Difference between revisions
Sara Mohsin (talk | contribs) No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Waldenström's macroglobulinemia}} | {{Waldenström's macroglobulinemia}} | ||
{{CMG}}{{AE}}{{S.M.}}{{MGS}} | {{CMG}}; {{AE}} {{S.M.}}, {{MGS}}; {{GRR}} {{Nat}} | ||
==Overview== | ==Overview== | ||
Revision as of 17:24, 8 April 2019
|
Waldenström's macroglobulinemia Microchapters |
|
Differentiating Waldenström's macroglobulinemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Waldenström's macroglobulinemia screening On the Web |
|
American Roentgen Ray Society Images of Waldenström's macroglobulinemia screening |
|
Directions to Hospitals Treating Waldenström's macroglobulinemia |
|
Risk calculators and risk factors for Waldenström's macroglobulinemia screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2], Mirdula Sharma, MBBS [3]; Grammar Reviewer: Natalie Harpenau, B.S.[4]
Overview
According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for Waldenström macroglobulinemia.
Screening
According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for Waldenström macroglobulinemia.[1]
References
- ↑ Recommendations. US preventive services task force(2015) http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=waldenstrom+macroglobulinemia Accessed on November 10, 2015